Inflammatory and oxidative and nitrosative stress cascades as new drug targets in myalgic encephalomyelitis and chronic fatigue syndrome

Modern Trends in Pharmacopsychiatry

Volumn 28, Issue , 2013, Pages 162-174

  Maes, Michael ^a  

^a Piyavate Hospital   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADALIMUMAB; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AZITHROMYCIN; BETA INTERFERON; CARNITINE; CIDOFOVIR; CURCUMIN; CYTOKINE; DOXYCYCLINE; EPIGALLOCATECHIN GALLATE; ETANERCEPT; FOSCARNET SODIUM; GLUTATHIONE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MACROPHAGE ACTIVATING FACTOR; MINOCYCLINE; OMEGA 3 FATTY ACID; QUERCETIN; RINTATOLIMOD; RITUXIMAB; UBIDECARENONE; VALACICLOVIR; VALGANCICLOVIR; ZINC; NITRIC ACID DERIVATIVE;

ANTIMICROBIAL THERAPY; ARTICLE; AUTOIMMUNE DISEASE; AUTONOMIC DYSFUNCTION; BACTERIAL INFECTION; BACTERIAL TRANSLOCATION; CARDIOVASCULAR DISEASE; CHLAMYDIAL PNEUMONIA; CHRONIC FATIGUE SYNDROME; COGNITIVE DEFECT; COGNITIVE THERAPY; CYTOMEGALOVIRUS INFECTION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DRUG TARGETING; ENCEPHALOMYELITIS; EPSTEIN BARR VIRUS INFECTION; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HUMAN; HYPERALGESIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; INFLAMMATION; KINESIOTHERAPY; MALAISE; MUSCLE WEAKNESS; MYCOPLASMOSIS; NITROSATIVE STRESS; OXIDATIVE STRESS; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; Q FEVER; RISK FACTOR; SIGNAL TRANSDUCTION; SLEEP DISORDER; VIRUS INFECTION; ANIMAL; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; FATIGUE SYNDROME, CHRONIC; HUMANS; INFLAMMATION; NITRATES; OXIDATIVE STRESS; RISK FACTORS;

EID: 84880805148     PISSN: 16622685     EISSN: 16624505     Source Type: Book Series    
DOI: 10.1159/000343982     Document Type: Article

References (62)

1. Fukuda K, Straus SE, Hickie I, Sh arpe M, Dobbins JG, Komaroff AL: The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Intern Med 1994;121:953-959
2. Nacul LC, Lacerda EM, Campion P, Pheby D, Drachler Mde L, Leite JC, Poland F, Howe A, Fayyaz S, Molokhia M: The functional status and wellbeing of people with myalgic encephalomyelitis/ chronic fatigue syndrome and their carers. BMC Publ Health 2011;11:402
3. Herrell R, Goldberg J, Hartman S, Belcourt M, Schmaling K, Buchwald D: Chronic fatigue and chronic fatigue syndrome: A co-Twin control study of functional status. Qual Life Res 2002; 11:463-471
4. Komaroff AL, Fagioli LR, Doolittle TH, Gandek B, Gleit MA, Guerriero RT, Kornish RJ 2nd, Ware NC, Ware JE Jr, Bates DW: Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med 1996;101:281-290
5. Cairns R, Hotopf M: A systematic review describing the prognosis of chronic fatigue syndrome. Occup Med (Lond) 2005;55:20-31
6. Carruthers BM, Van De Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles AC, Speight N, Vallings R, Bateman L, Baumgarten-Austrheim B, Bell DS, Carlo-Stella N, Chia J, Darragh A, Jo D, Lewis D, Light AR, Marshall-Gradisbik S, Mena I, Mikovits JA, Miwa K, Murovska M, Pall ML, Stevens S: Myalgic encephalomyelitis. International Consensus Criteria. J Intern Med 2011;270: 327-338
7. Maes M, Twisk FNM, Johnson C: Myalgic encephalomyelitis (ME), chronic fatigue syndrome (CFS), and chronic fatigue (CF) are distinguished accurately: Results of supervised learning techniques applied on clinical and inflammatory data. Psychiatr Res 2012, Apr 20, Epub ahead of print
8. WHO: International Classification of Diseases, revision 10 (ICD-10). 1992; G93.3
9. Twisk FN, Maes M: A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. Neuro Endocrinol Lett 2009;30:284-299
10. Maes M: Nooit meer moe: CVS ontmaskerd. Brugge, Zorro Uitgevers, 2012
11. Maes M: An intriguing and hitherto unexplained co-occurrence: Depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:784-794
12. Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG: A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res 2002;52:501-509
13. Maes M: Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry 2009;22:75-83
14. Maes M, Twisk FN: Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Med 2010;8:35
15. Maes M, Twisk FN: Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: Disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS. Neuro Endocrinol Lett 2009; 30:677-693
16. Maes M, Twisk FN, Kubera M, Ringel K: Evidence for inflammation and activation of cell-mediated immunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Increased interleukin-1, tumor necrosis factor-A, PMN-elastase, lysozyme and neopterin. J Affect Disord 2012;136:933-939
17. Komaroff AL, Cho TA: Role of infection and neurologic dysfunction in chronic fatigue syndrome. Semin Neurol 2011; 31:325-337
18. Arnett SV, Alleva LM, Korossy-Horwood R, Clark IA: Chronic fatigue syndrome: A neuroimmunological model. Med Hypotheses 2011;77:77-83
19. Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG: Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009;7:96
20. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G: Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009;8:287-291
21. Vojdani A, Lapp CW: Interferon-induced proteins are elevated in blood samples of patients with chemically or virally induced chronic fatigue syndrome. Immunopharmacol Immunotoxicol 1999;21:175-202
22. Maes M, Mihaylova I, Leunis JC: Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett 2006;27:615-621
23. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA: A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 2010;24:1209-1217
24. White AT, Light AR, Hughen RW, Bateman L, Thomas B, Martins TB, et al: Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome. Psychophysiology 2010;47:615-624
25. Landay AL, Jessop C, Lennette ET, Levy JA: Chronic fatigue syndrome: Clinical condition associated with immune activation. Lancet 1991;338:707-712
26. Klimas NG, Salvato FR, Morgan R, Fletcher MA: Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990;28:1403-1410
27. Patarca-Montero R, Antoni M, Fletcher MA, Klimas NG: Cytokine and other immunologic markers in chronic fatigue syndrome and their relation to neuropsychological factors. Appl Neuropsychol 2001;8:51-64
28. Leonard B, Maes M: Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobeh Rev 2012; 36:764-785
29. Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, Peakman M: High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol 2004;135:294-302
30. Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, Antoni M, Broderick G, Klimas NG: Biomarkers in chronic fatigue syndrome: Evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One 2010;5:e10817
31. Klimas NG, Salvato FR, Morgan R, Fletcher MA: Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990;28:1403-1410
32. Mihaylova I, DeRuyter M, Rummens JL, Bosmans E, Maes M: Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: Evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. Neuro Endocrinol Lett 2007;28:477-483
33. Behan WM, More IA, Behan PO: Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol 1991;83:61-65
34. Myhill S, Booth NE, McLaren-Howard J: Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009;2:1-16
35. Gardner A, Johansson A, Wibom R, Nennesmo I, von Dobeln U, Hagenfeldt L, Hallstrom T: Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord 2003;76:55-68
36. Maes M, Mihaylova I, Bosmans E: Not in the mind of neurasthenic lazybones but in the cell nucleus: Patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol Lett 2007;28:456-462
37. Maes M, Mihaylova I, Kubera M, Bosmans E: Not in the mind but in the cell: Increased production of cyclooxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol Lett 2007;28:463-469
38. Maes M, Twisk FN, Kubera M, Ringel K, Leunis JC, Geffard M: Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome. J Affect Disord 2012;136:909-917
39. Tirelli U, Marotta G, Improta S, Pinto A: Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 1994;40:601-608
40. Barnden LR, Crouch B, Kwiatek R, Burnet R, Mernone A, Chryssidis S, Scroop G, Del Fante P: A brain MRI study of chronic fatigue syndrome: Evidence of brainstem dysfunction and altered homeostasis. NMR Biomed 2011;24: 1302-1312
41. Okada T, Tanaka M, Kuratsune H, Watanabe Y, Sadato N: Mechanisms underlying fatigue: A voxel-based morphometric study of chronic fatigue syndrome. BMC Neurol 2004;4:14
42. Schwartz RB, Komaroff AL, Garada BM, Gleit M, Doolittle TH, Bates DW, Vasile RG, Holman BL: SPECT imaging of the brain: Comparison of findings in patients with chronic fatigue syndrome, AIDS dementia complex, and major unipolar depression. AJR Am J Roentgenol 1994; 162:943-951
43. Biswal B, Kunwar P, Natelson BH: Cerebral blood flow is reduced in chronic fatigue syndrome as assessed by arterial spin labeling. J Neurol Sci 2011;301:9-11
44. Patrick Neary J, Roberts AD, Leavins N, Harrison MF, Croll JC, Sexsmith JR: Prefrontal cortex oxygenation during incremental exercise in chronic fatigue syndrome. Clin Physiol Funct Imaging 2008; 28:364-372
45. Schmaling KB, Lewis DH, Fiedelak JI, Mahurin R, Buchwald DS: Single-photon emission computerized tomography and neurocognitive function in patients with chronic fatigue syndrome. Psychosom Med 2003;65:129-136
46. Jason LA, Corradi K, Gress S, Williams S, Torres-Harding S: Causes of death among patients with chronic fatigue syndrome. Health Care Women Int 2006; 27:615-626
47. Scott LV, Medbak S, Dinan TG: Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. Acta Psychiatr Scand 1998;97: 450-457
48. Hilgers A, Frank J: Chronic fatigue syndrome: Immune dysfunction, role of pathogens and toxic agents and neurological and cardial changes. Wien Med Wochenschr 1994;144:399-406
49. Maes M, Mihaylova I, Leunis JC: In chronic fatigue syndrome, the decreased levels of omega-3 poly-unsaturated fatty acids are related to lowered serum zinc and defects in T cell activation. Neuro Endocrinol Lett 2005;26:745-751
50. Naess H, Sundal E, Myhr KM, Nyland HI: Postinfectious and chronic fatigue syndromes: Clinical experience from a tertiary-referral centre in Norway. In Vivo 2010;24:185-188
51. Nicolson GL, Gan R, Haier J: Multiple co-infections (mycoplasma, chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: Association with signs and symptoms. APMIS 2003;111:557-566
52. Strickland PS, Levine PH, Peterson DL, O'Brien K, Fears T: Neuromyasthenia and chronic fatigue syndrome (CFS) in Northern Nevada/California: A ten-year follow-up of an outbreak. J Chron Fatigue Syndr 2001;9:3-14
53. Zhang L, Gough J, Christmas D, Mattey DL, Richards SC, Main J, Enlander D, Honeybourne D, Ayres JG, Nutt DJ, Kerr JR: Microbial infections in eight genomic subtypes of chronic fatigue syndrome/ myalgic encephalomyelitis. J Clin Pathol 2010;63:156-164
54. van Langenberg DR, Gibson PR: Systematic review: Fatigue in inflammatory bowel disease. Aliment Pharmacol Ther 2010;32:131-143
55. Kang HK, Natelson BH, Mahan CM, Lee KY, Murphy FM: Post-Traumatic stress disorder and chronic fatigue syndromelike illness among Gulf War veterans: A population-based survey of 30,000 veterans. Am J Epidemiol 2003;57:141-148
56. Dobbins JG, Natelson BH, Brassloff I, Drastal S, Sisto S-A: Physical, behavioral and psychological risk factors for chronic fatigue syndrome: A central role for stress? J Chron Fatigue Syndr 1995; 1:43-58
57. Maes M, Coucke F, Leunis JC: Normalization of the increased translocation of endotoxin from Gram-negative enterobacteria (leaky gut) is accompanied by a remission of chronic fatigue syndrome. Neuro Endocrinol Lett 2007;28:739-744
58. Jammes Y, Steinberg JG, Mambrini O, Bregeon F, Delliaux S: Chronic fatigue syndrome: Assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med 2005;257:299-310
59. Heinonen I, Saltin B, Kemppainen J, Sipila HT, Oikonen V, Nuutila P, Knuuti J, Kalliokoski K, Hellsten Y: Skeletal muscle blood flow and oxygen uptake at rest and during exercise in humans: A PET study with nitric oxide and cyclooxygenase inhibition. Am J Physiol Heart Circ Physiol 2011;300:H1510-H1517
60. Latremoliere A, Woolf CJ: Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J Pain 2009;10:895-926
61. Suhadolnik RJ, Reichenbach NL, Hitzges P, Adelson ME, Peterson DL, Cheney P, Salvato P, Thompson C, Loveless M, Muller WE, et al: Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. In Vivo 1994;8:599-604
62. Fluge , Mella O: Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: A preliminary case series. BMC Neurol 2009;9:28